Raised 2026 adjusted EPS guidance by $0.60 to $7.90-$8.10
CVS Health reported a strong FY2026 Q2, beating expectations across all segments and raising full-year EPS and cash flow guidance. Management highlighted significant margin recovery in the Medicare Advantage business and strong execution in retail pharmacy, while noting emerging headwinds for 2027 related to 340B program restrictions and a highly competitive PBM selling season. Raised FY2026 adjusted EPS guidance by $0.60 to $7.90-$8.10 and operating cash flow by $2B to at least $11.5B.
Buzzberg readRaised 2026 adjusted EPS guidance by $0.60 to $7.90-$8.10CVS Health reported a strong FY2026 Q2, beating expectations across all segments and raising full-year EPS and cash flow guidance. Management highlighted significant margin recovery in the Medicare Advantage business and strong execution in retail pharmacy, while noting emerging headwinds for 2027 related to 340B program restrictions and a highly competitive PBM selling season. Raised FY2026 adjusted EPS guidance by $0.60 to $7.90-$8.10 and operating cash flow by $2B to at least $11.5B.Read full analysisCollapse analysis
CVS Health reported a strong FY2026 Q2, beating expectations across all segments and raising full-year EPS and cash flow guidance. Management highlighted significant margin recovery in the Medicare Advantage business and strong execution in retail pharmacy, while noting emerging headwinds for 2027 related to 340B program restrictions and a highly competitive PBM selling season. Raised FY2026 adjusted EPS guidance by $0.60 to $7.90-$8.10 and operating cash flow by $2B to at least $11.5B.
Provided an early FY2027 EPS floor of $8.44, representing ~13% growth off the adjusted 2026 baseline.
Partnering with Eli Lilly and Novo Nordisk to capture the cash-pay GLP-1 market via direct-to-consumer channels as employers restrict coverage.
Experiencing margin pressure in the Caremark PBM business due to pharma manufacturers restricting the 340B program.
HEALTH_SERVICES revenue$52B
reported
HEALTHCARE_BENEFITS revenue$37B
reported
PHARMACY_CONSUMER_WELLNE revenue$34B
reported
Revenue$106.096B
+6% QoQ
What changed this quarter
01
Guidance
Raised 2026 adjusted EPS guidance by $0.60 to $7.90-$8.10
Guidance · revenue to $414B
02
Guidance
2027 EPS floor of $8.44, 13% growth
Guidance · revenue to $414B
03
Margins
2027 PBM headwinds from 340B and client losses
Reported gross margin was 14.84%, reinforcing the quarter's better-than-guided profitability.
04
Margins
Aetna margin recovery ahead of expectations
Reported gross margin was 14.84%, reinforcing the quarter's better-than-guided profitability.
AI, capex & demand read
AI
Platform & monetization
Management is deploying AI across the enterprise to improve clinical quality, reduce provider burden, and enhance member and provider experiences, with initiatives like AI-enabled claims processing and conversational AI in pharmacies. They see AI as central to moving from a consumer-based healthcare company to a consumer-based healthcare technology business, with early results showing improved eff
Demand
Bookings & conversion
Management noted strong prescription volume growth (7% same-store increase) and continued momentum in pharmacy services, but flagged a slightly lower retention rate in the PBM selling season and 340B pressure as 2027 headwinds. Aetna Medicare and commercial membership trends were better than expected in 2026.
Capex
Investment and capacity
No explicit capex guidance or quantitative capex figures were provided, but management repeatedly emphasized deliberate and intentional investments in technology, AI, and infrastructure across segments to drive efficiency and growth.
Tone · Confident
Management expressed strong confidence in execution, raised guidance, and pulled forward 2027 commentary, but were measured about specific headwinds, demonstrating nuanced optimism.
Supply-chain alpha
A1
Employer pushback on GLP-1 costs is accelerating a shift toward direct-to-consumer, cash-pay models.
“affordability challenges mean not all employers can cover GLP-1s for weight loss. As more consumers seek access to these therapies outside of traditional benefit designs, CVS Health's comprehensive direct-to-consumer platform provides...”
The No Surprises Act's Independent Dispute Resolution (IDR) process is driving elevated commercial risk trends.
“No surprises act was put in for a reason to keep patients out of the middle... but the dispute resolution process is clearly being abused by a small group of players.”
Employer pushback on GLP-1 costs is accelerating a shift toward direct-to-consumer, cash-pay models. — As commercial insurance balks at obesity drug costs, pharmaceutical companies are increasingly relying on direct-to-consumer cash-pay channels, which could alter gross-to-net pricing dynamics and volume growth.
“Later this year, through our new partnership with Eli Lilly, eligible ZepFound and Foundeo patients will be able to access cash pay pricing for same-day pickup directly through CVS Health's app or in our stores.”
… CVS Health's comprehensive direct-to-consumer platform provides a trusted, convenient, and affordable pathway to care. MinuteClinic's 24-7 virtual weight management offering is the lowest cost option in the industry, connecting eligible patients with a licensed clinician for just $29. Through our manufacturer relationships and CVS Pharmacy's omni-channel fulfillment capabilities, Thank you for joining us. Later this year, through our new partnership with Eli Lilly, eligible ZepFound and Foundeo patients will be able to access cash pay pricing for same-day pickup directly through CVS Health's app or in our stores. This builds on our existing relationship with Novo to dispense oral and injectable with Gove, making CVS Pharmacy a convenient, affordable destination for all FDA-approved GLP-1s. As more consumers begin these therapies, the role of our nearly 30,000 pharmacists is an important differentiator for us. They help patients manage common side effects, answer questions, and ensure they stay on therapy. These trusted pharmacist relationships and our omni-channel capabilities are especially important for seniors. With the launch of Medicare Bridge last month, CVS Pharmacy …
Employer pushback on GLP-1 costs is accelerating a shift toward direct-to-consumer, cash-pay models. — As commercial insurance balks at obesity drug costs, pharmaceutical companies are increasingly relying on direct-to-consumer cash-pay channels, which could alter gross-to-net pricing dynamics and volume growth.
“This builds on our existing relationship with Novo to dispense oral and injectable with Gove, making CVS Pharmacy a convenient, affordable destination for all FDA-approved GLP-1s.”
… in the industry, connecting eligible patients with a licensed clinician for just $29. Through our manufacturer relationships and CVS Pharmacy's omni-channel fulfillment capabilities, Thank you for joining us. Later this year, through our new partnership with Eli Lilly, eligible ZepFound and Foundeo patients will be able to access cash pay pricing for same-day pickup directly through CVS Health's app or in our stores. This builds on our existing relationship with Novo to dispense oral and injectable with Gove, making CVS Pharmacy a convenient, affordable destination for all FDA-approved GLP-1s. As more consumers begin these therapies, the role of our nearly 30,000 pharmacists is an important differentiator for us. They help patients manage common side effects, answer questions, and ensure they stay on therapy. These trusted pharmacist relationships and our omni-channel capabilities are especially important for seniors. With the launch of Medicare Bridge last month, CVS Pharmacy is helping seniors navigate the program and access these therapies more easily. At the same time, we're creating a new source of prescription volume as affordability barriers come down. Across CBS …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.